Otonomy Announces Presentation of OTO-413 Clinical Results at AAO-HNS Annual Meeting

Rhea-AI Summary

Otonomy, Inc. (Nasdaq: OTIC) announced the presentation of clinical results from its OTO-413 Phase 1/2 trial at the AAO-HNS Annual Meeting in Los Angeles on October 3, 2021. The results will be shared by Dr. Peter G. Volsky, highlighting the treatment's potential for patients suffering from speech-in-noise hearing impairment, a common issue in noise-induced and age-related hearing loss. Otonomy focuses on innovative therapeutics for neurotology, leveraging unique drug delivery technology to address significant medical needs in hearing loss and tinnitus.

Positive

• Successful presentation of OTO-413 Phase 1/2 trial clinical results.
• Highlighting the potential treatment benefit for speech-in-noise hearing impairment.

Negative

• None.

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-413 Phase 1/2 trial at the upcoming American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS) Annual Meeting to be held in Los Angeles October 3-6, 2021. The oral presentation will be delivered on October 3, 2021 at 3:15 p.m. PT by Peter G. Volsky, M.D., Assistant Professor of Otology and Neurotology at Eastern Virginia Medical School. Dr. Volsky was an investigator in the trial during his prior clinical service with South Florida ENT Associates.

“Difficulty understanding conversations in a noisy environment is a common complaint of patients presenting for hearing loss treatment including patients with noise-induced and age-related hearing loss,” said David A. Weber, Ph.D., president and CEO of Otonomy. “Presentation of these positive clinical results for OTO-413 highlights its potential treatment benefit for this large population of patients with speech-in-noise hearing impairment.”

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information please visit www.otonomy.com.

Contacts:

Media Inquiries:
Spectrum Science
Chloé-Anne Ramsey
Vice President
404.865.3601
cramsey@spectrumscience.com

Investor Inquiries:
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

FAQ

What were the results of the OTO-413 Phase 1/2 trial by Otonomy?

The results indicated potential treatment benefits for patients with speech-in-noise hearing impairment, a common issue associated with hearing loss.

When will Otonomy present its OTO-413 trial results?

Otonomy will present the OTO-413 Phase 1/2 trial results on October 3, 2021, at the AAO-HNS Annual Meeting.

What is the significance of the OTO-413 trial for Otonomy?

The trial results are significant as they highlight a new potential treatment for a large population suffering from hearing impairment.

How does Otonomy's drug delivery technology work?

Otonomy's drug delivery technology allows for sustained drug exposure from a single local administration, effectively targeting ear-related conditions.